文献检索

查找使用阿拉丁产品的科研文献

检索与阿拉丁产品相关的同行评审论文、DOI、PubMed 编号、期刊、作者、CAS 号及研究领域。

科研影响力快照

与阿拉丁产品相关的已发表科研成果

在搜索之前,这些指标可帮助访客快速了解产品关联科研的规模与质量。

346,364+ SCI 论文 与阿拉丁产品引用相关
2,295,288.15 总影响因子 匹配文献记录中影响因子的总和
81.20 最高期刊影响因子 匹配期刊中的最高 IF
6.63 平均期刊影响因子 匹配文献的平均 IF

参考指标 指标基于阿拉丁文献引用数据库及期刊影响因子记录。文献关联仅供科研参考,请以原始文献为准。

热门产品

视图 列表 网格

2 项

设置提升方向
EGb761
INDUSTRIAL CROPS AND PRODUCTS · 2015 · IF 2.837

Synergistic, additive and antagonistic effects of Potentilla fruticosa combined with EGb761 on antioxidant capacities and the possible mechanism

Shanshan Wang,Dongmei Wang,Zehua Liu

Potentilla fruticosa and EGb 761 ( Ginkgo biloba extracts) have been applied in traditional medicine and exhibit antioxidant properties. However, there is very little scientific evidence to support their use in combination. In this study, a bio-guided chromatographic fractionation strategy was used to obtain two effective fractions (C-3 and D-2) from the acetone crude extracts (A) of P. fruticosa leaves. Isobolographic analysis indicated that the combination of A   +   EGb had largely demonstrated synergism and 5:1 (A:EGb) displayed the best synergistic effect. In addition, C-3   +   EGb exhibited a similar result as A   +   EGb, synergism in DPPH and ABTS assays, additive in FRAP assay. While D-2   +   EGb showed only additive effect. The possible mechanism behind the synergism was explored by RP-HPLC. The changes in the total phenolic and flavonoids content were also investigated. While chemical composition did not seem to change in the mixture, no new peaks appeared in the chromatogram of C-3   +   EGb mixture as compared to the individual chromatograms, no existing peaks disappeared either. Further studies were observed which may prove the possible mechanism responsible for the synergistic effect. Combinations of C-3 and 4 phenolic compounds in EGb ((+)-catechin, kaempferide, quercetin and isorhamnetin) were evaluated for their antioxidant capacities. Isorhamnetin showed synergism with C-3, and 5:1 exhibited the strongest synergism in DPPH ( γ   =   0.669) and ABTS ( γ   =   1.249), 1:1 in FRAP assays ( γ   =   1.385). Isorhamnetin was added to the other 6 phenolics in C-3 ((+)-catechin, caffeic acid, hyperoside, rutin, ellagic acid and quercetin), and the antioxidant capacity of mixtures was analyzed. For all combinations studied, caffeic acid   +   isorhamnetin displayed the greatest synergistic effect in various ratios by three antioxidant assays, the observed values were significantly higher than the expected values ( P   <   0.05) and 1:1 exhibited the strongest synergism in DPPH ( γ   =   0.711), ABTS ( γ   =   1.693) and FRAP ( γ   =   1.474) assays. Hyperoside   +   isorhamnetin also showed a slight synergism, but (+)-catechin   +   isorhamnetin exhibited an antagonism in DPPH assays. Thus, interaction of phytochemicals exist in extracts is likely responsible for the synergistic effects present in A   +   EGb, and caffeic acid   +   isorhamnetin may have played an important role. This study lends some credence to the concomitant use of P. fruticosa blended with EGb, which could be useful for developing new medicines and functional products from P. fruticosa and EGb.

CAS / MDL: 118-75-2
研究领域: 药理学 · 生物化学 · 药物化学
✓ 已验证 产品关联 DOI 高影响因子
查看原文 查看 PubMed
GYNECOLOGICAL ENDOCRINOLOGY · 2022 · IF 2.277

Ginkgo biloba extract 761 reduces vascular permeability of the ovary and improves the symptom of ovarian hyperstimulation syndrome in a rat model

Jie Zhang,Jie Huang,Xinhuan He,Ning Li,Yu Miao,Beiqing Li,Xiaoguang Shao,Ningning Wang

Aims Ginkgo biloba extract (EGb) has been widely applied in the treatment of cerebrovascular and neurological diseases. However, the effect of EGb761 on ovarian hyperstimulation syndrome (OHSS), a vascular disorder and life-threatening complication of in vitro fertilization and intracytoplasmic sperm injection therapy (IVF/ICSI), has not been evaluated.Materials and methods Forty female Wistar rats aged 22-days old (D22) were divided into eight groups: Control rats received intraperitoneal injection of saline for five consecutive days (D22–D26); OHSS model group received 10 IU equine chorionic gonadotropin (eCG) for four consecutive days (D22–D25) and 30 IU of human chorionic gonadotropin (hCG) on the 5th day (D26); Prophylactic treatment group received three doses of EGb761 (50, 100, and 200 mg/kg/day) 1 h before injection of eCG (hCG) for seven consecutive days; Therapeutic treatment group received three doses of EGb761 (50, 100, and 200 mg/kg/day) 48 h after injection of eCG (hCG) for seven consecutive days.Results All three doses of EGb761 therapeutic medication significantly reduced ovarian mass index of OHSS model rats (p ≤ .01). Furthermore, therapeutic treatment group exhibited improved vascular permeability, decreased estradiol and progesterone levels, lower corpus luteum, and higher follicle numbers compared with the OHSS model. Elevated protein expression of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in both ovary and kidney of the OHSS model was restrained by EGb761 therapeutic treatment.Conclusions EGb761 therapeutic medication decreases vascular permeability in OHSS rat model by inhibiting VEGF and VEGFR expression, which may contribute to the treatment of OHSS.

CAS / MDL: 68-12-2
研究领域: 生殖医学 · 药理学 · 血管生物学
✓ 已验证 产品关联 DOI PubMed 高影响因子
查看原文 查看 PubMed
已复制

文献关联基于可获得的产品、CAS、DOI 及引用记录。收录不代表作者或出版方对阿拉丁产品的背书,请以原始文献为准。